Compound profile

Retatrutide

Eli Lilly's investigational triple agonist

How retatrutide works, what its Phase 3 TRIUMPH trials showed, trial dosing, side effects, and why it isn't available yet outside clinical trials.

How it works

Three hormone receptors at once

Semaglutide hits one receptor, tirzepatide two. Retatrutide adds a third: glucagon.

GLP-1

Slows the stomach and reduces appetite, the same pathway as semaglutide.

GIP

Boosts insulin release after meals and affects fat metabolism, added in tirzepatide.

Glucagon

Thought to raise energy use and liver fat burning. This is what's new.

Uses: obesity, type 2 diabetes, and related conditions like sleep apnea and knee osteoarthritis pain in Lilly's trials.

Evidence

What the Phase 3 trials showed

Average weight loss on the 12mg dose over 80 weeks, versus placebo.

TRIUMPH-1, obesity
-28.3%vs -2.2% on placebo

2,339 adults without diabetes. 45% on 12mg lost at least 30% of their weight.

Eli Lilly topline results, May 2026

TRIUMPH-2, with type 2 diabetes
-20.8%vs -4.0% on placebo

1,152 adults with obesity and type 2 diabetes. A1C fell about 1.5 points.

Eli Lilly topline results, July 2026

TRIUMPH-3, heart disease
-22.6%vs -3.2% on placebo

1,949 adults with severe obesity and heart disease. Not designed to show fewer heart events.

Eli Lilly topline results, July 2026

These are company-reported topline results, not yet fully peer reviewed. The earlier Phase 2 trial (NEJM 2023) showed -24.2% at 48 weeks. Full breakdown: retatrutide human studies.

Trial dosing

How it was dosed in trials

Weekly injections under medical supervision. Not guidance for using unregulated material.

Start and step up
2mg once weekly

Doses were raised about every 4 weeks. In Phase 2, starting at 2mg instead of 4mg meant fewer stomach side effects.

Maintenance doses tested
4, 9 or 12mg weekly

Phase 3 tested 4mg, 9mg and 12mg. A final approved label could differ.

TRIUMPH-1 doseAverage weight changeLost 30% or moreStopped for side effects
4mg-19.0%15.3%4.1%
9mg-25.9%37.9%6.9%
12mg-28.3%45.3%11.3%
Placebo-2.2%0.5%4.9%
Side effects

Side effects in TRIUMPH-1

Mostly stomach-related, worst while the dose is going up.

Retatrutide 12mgPlacebo
Nausea42.4%14.8%
Diarrhea32.0%13.5%
Vomiting25.3%4.8%
Stopped for side effects11.3%4.9%

Other warnings for this drug class include gallbladder problems and pancreatitis. Red flags and more: peptide side effects.

Legal status

Not available yet

  • Not approved anywhere. Lilly plans to file with the FDA in the first quarter of 2027. Approval before late 2027 is unlikely.
  • Clinical trials only. That's the only legal way to get it today. It isn't covered by the 2026 compounding policy.
  • "Research" retatrutide is a bigger red flag than most. It's an active trial drug being sold outside Lilly's quality controls, and the FDA has sent warning letters to sellers marketing it for human use.

Approved options today: tirzepatide (Mounjaro, Zepbound) and semaglutide. More in how to get peptides legally.

A friendly doctor talking with a fit young woman about treatment options in a bright clinic
Track it

What to track

  • Weight and waist weekly, body composition every month or two
  • HbA1c, fasting glucose and a lipid panel
  • Protein and strength training, to protect muscle during fast weight loss

The dashboard logs weight and side effects at each dose step, and Lab Analysis tracks your markers.

A fit young man stepping onto a smart scale in a bright bathroom while checking his phone

Common question: why does my skin hurt on retatrutide?

Skin sensitivity (dysesthesia) is a documented retatrutide side effect. Read retatrutide skin sensitivity and why injections can hurt more, or browse more community questions.

Frequently asked questions

What is retatrutide?

Retatrutide (LY3437943) is Eli Lilly's investigational weekly injection that activates three hormone receptors at once: GIP, GLP-1 and glucagon. Semaglutide acts on GLP-1 alone and tirzepatide on GIP and GLP-1. It is being studied for obesity, type 2 diabetes and related conditions.

Is retatrutide FDA-approved?

No. Retatrutide has completed several Phase 3 trials but is not approved by the FDA or any other regulator. Eli Lilly plans to submit its first application in the first quarter of 2027, and approval before late 2027 is unlikely.

How much weight did people lose on retatrutide?

In Lilly's TRIUMPH-1 Phase 3 trial, adults with obesity on the 12mg dose lost an average of 28.3% of their body weight over 80 weeks, versus 2.2% on placebo, and 45% lost at least 30%. In TRIUMPH-2 (with type 2 diabetes) the figure was 20.8%, and in TRIUMPH-3 (with heart disease) 22.6%. These are company-reported topline results.

What dose of retatrutide was used in trials?

Trials used weekly injections starting at 2mg, raised about every four weeks to maintenance doses of 4mg, 9mg or 12mg in Phase 3. In Phase 2, starting at 2mg rather than 4mg led to fewer stomach side effects. This describes supervised trial dosing, not guidance for self-use.

What are the side effects of retatrutide?

Mostly stomach-related. In TRIUMPH-1 on 12mg, 42.4% had nausea, 32.0% diarrhea and 25.3% vomiting, versus 14.8%, 13.5% and 4.8% on placebo, and 11.3% stopped because of side effects versus 4.9%. Gallbladder problems and pancreatitis are warnings for this drug class.

How is retatrutide different from tirzepatide?

Tirzepatide activates GIP and GLP-1 receptors and is FDA-approved as Mounjaro and Zepbound. Retatrutide adds glucagon receptor activity and produced more weight loss in its own trials, but no head-to-head trial has compared them, and retatrutide is not yet approved.

Can I buy retatrutide?

Not legally for human use. The only legal access today is through clinical trials. Retatrutide sold online as a research chemical is not made under Lilly's trial controls, is not covered by the 2026 compounding policy, and has drawn FDA warning letters to sellers marketing it for human use.

When will retatrutide be available?

Eli Lilly plans to file with the FDA in the first quarter of 2027. A standard review would put a possible approval in late 2027 or 2028, with pharmacy availability after that, if it is approved.

Where to buy: why there is no legal way yet, and what to do instead, in where to buy retatrutide.

Track your weight-loss journey

Log weight, doses, side effects and labs in one place, whatever medication your clinician prescribes. Free.

Sources

  1. Eli Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. investor.lilly.com
  2. Eli Lilly. Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). July 23, 2026. press release
  3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315
  4. Bajaj HS, et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial. Lancet. 2026. PMID 42250575

This content is for informational purposes only and is not medical advice. Retatrutide is an investigational drug, not approved by the FDA or any regulator, and not legally available for human use outside clinical trials. Always consult a qualified healthcare provider about weight management.